secukinumab
Selected indexed studies
- Bimekizumab versus Secukinumab in Plaque Psoriasis. (N Engl J Med, 2021) [PMID:33891380]
- Secukinumab in plaque psoriasis--results of two phase 3 trials. (N Engl J Med, 2014) [PMID:25007392]
- Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. (Lancet, 2023) [PMID:36746171]
_Worker-drafted node — pending editorial review._
Connections
secukinumab is a side effect of
Sources
- Bimekizumab versus Secukinumab in Plaque Psoriasis. (2021) pubmed
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. (2023) pubmed
- Secukinumab in plaque psoriasis--results of two phase 3 trials. (2014) pubmed
- Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. (2023) pubmed
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. (2015) pubmed
- Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. (2021) pubmed
- Secukinumab in the treatment of hidradenitis suppurativa. (2023) pubmed
- Secukinumab: A Review in Ankylosing Spondylitis. (2019) pubmed
- Secukinumab: A Review in Psoriatic Arthritis. (2021) pubmed
- Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. (2021) pubmed